Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

21.6%

8 terminated/withdrawn out of 37 trials

Success Rate

75.8%

-10.7% vs industry average

Late-Stage Pipeline

30%

11 trials in Phase 3/4

Results Transparency

84%

21 of 25 completed trials have results

Key Signals

2 recruiting21 with results6 terminated

Enrollment Performance

Analytics

Phase 1

13(35.1%)

Phase 2

12(32.4%)

Phase 3

11(29.7%)

Early Phase 1

1(2.7%)

37Total

Phase 1(13)

Phase 2(12)

Phase 3(11)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (37)

Showing 20 of 37 trials

NCT06636786Phase 2Recruiting

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)

Role: collaborator

NCT07473752Phase 1Completed

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

Role: lead

NCT07464535Phase 1Completed

A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects

Role: lead

NCT07204080Phase 2Not Yet Recruiting

(TNX-1500) in Kidney Transplant Recipients

Role: collaborator

NCT07413367Phase 1Active Not Recruiting

A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants

Role: lead

NCT04789148Phase 1Recruiting

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

Role: collaborator

NCT06045793Phase 2Terminated

Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)

Role: lead

NCT06955650Early Phase 1Completed

First-in-man Imaging of a New PET Radiotracer for Oxytocin Receptors

Role: collaborator

NCT05679908Phase 2Completed

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

Role: lead

NCT02829814Phase 3Terminated

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

Role: lead

NCT02589275Phase 3Completed

A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients

Role: lead

NCT05686408Phase 2Completed

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

Role: lead

NCT02436096Phase 3Completed

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia

Role: lead

NCT03110575Phase 3Terminated

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

Role: lead

NCT03841773Phase 3Terminated

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

Role: lead

NCT02421679Phase 2Completed

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

Role: lead

NCT03508700Phase 3Completed

A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD

Role: lead

NCT05273749Phase 3Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia

Role: lead

NCT05472090Phase 2Completed

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

Role: lead

NCT05216510Phase 1Terminated

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

Role: lead